SATELLITE SESSION 3:
Helsinki, Finland | 1st July 2024
Watch Prof. John Vissing and Prof. Sven Meuth share their clinical experience and review aspects of disease management that matter most to patients living with generalised myasthenia gravis (gMG) in this Alexion-sponsored Satellite Session at the 10th Congress of the European Academy of Neurology held on July 1st, 2024 in Helsinki, Finland.
img example

Prof. John Vissing

Professor of Neurology at the University of Copenhagen, Denmark, Director of the Copenhagen Neuromuscular Center at the National Hospital, Rigshospitalet

John Vissing is professor of Neurology at the University of Copenhagen, Denmark, and the Director of the Copenhagen Neuromuscular Center at the National Hospital, Rigshospitalet, in Copenhagen since 1998.

He graduated in 1986 as MD from the University of Copenhagen and was then a research fellow at University of Copenhagen and UT, Southwestern Medical Center in Dallas, USA. His research focuses on hereditary muscle diseases and myasthenia gravis. He has authored 490 scientific papers on neuromuscular diseases.

Prof. Dr. Sven Meuth

Professor at Department of Neurology, Institute of Translational Neurology and Neurology Clinic at the University of Münster

Sven Meuth is a Professor at Department of Neurology, Institute of Translational Neurology and Neurology Clinic at the University of Münster since 2010. His scientific interests include the investigation of animal models of autoimmune inflammation, ion channels in inflammation and degeneration and neuroimmune interaction.

For his scientific work on the functional expression of ion channels on T cells, Professor Meuth received the Helmut-Bauer-Award from the University of Göttingen in 2009 and the Sobek-Young-Investigator-Award in 2010.

Professor Meuth studied human medicine and neurobiology at the Otto-von-Guericke University in Magdeburg, Germany, and received his PhD titles in 2005 (Dr. med.) and 2007 (Dr. rer. nat.) at the associated Institute of Physiology. He began his specialization in neurology at the Neurological University Würzburg in 2004 and was appointed as full professor at the Clinic of Neurology associated with the University of Münster in 2010.

This company-sponsored symposium at the EAN 2024 was organised and funded by Alexion, AstraZeneca Rare Disease and intended for Healthcare Professionals. This presentation includes data relating to eculizumab and ravulizumab.​
Sign up now to be informed of our upcoming symposia, our latest educational updates, and to be alerted to our webinars, hosted by world leading rare disease experts
Keep me up to date

FIRST NAME*

SURNAME*

DISEASE AREA OF INTEREST*

Specialty*

EMAIL*

COUNTRY*

advance I am a healthcare professional registered in the EU I am not a
healthcare professional

SOLIRIS® (eculizumab) is indicated for the treatment of refractory generalised myasthenia gravis (gMG) in patients aged 6 years and above who are anti-acetylcholine receptor (AChR) antibody-positive.

ULTOMIRIS® (ravulizumab) is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are AChR antibody-positive.

Ravulizumab EU Summary of Product Characteristics
Eculizumab EU Summary of Product Characteristics

Prescribing information may differ from country to country. Please refer to your locally approved label and take this into consideration when viewing this information.

Please verify reimbursement status applicable in your country.

SAFETY INFORMATION
Please report any adverse events via your national reporting system. Adverse events can also be reported to Alexion Pharmaceuticals by the following link: https://contactazmedical.astrazeneca.com/